CG Oncology's net loss widens 29.9% to $56.9M as R&D spend climbs; cash at $984.5M

Filed November 6, 2026 · Period ending September 30, 2026 · Compared to 10-Q Nov 14, 2025 · ~1 min read

Key Changes

• high

  Net loss widened 29.9% to $56.9M, or $0.64 per share, driven by higher R&D and G&A expenses.

  MD&A: Results of Operations verify on EDGAR →
• high

  Cash, cash equivalents and marketable securities totaled $984.5M at Sept 30, 2026, with working capital of $961.3M.

  Liquidity and Capital Resources verify on EDGAR →
• high

  Operating cash outflow for the nine months was $151.1M, up 57.1% from $96.1M a year earlier.

  Cash Flow verify on EDGAR →